All-trans-retinoic acid (atRA), a biologically active form of Vitamin A and a cytodifferentiating agent is being successfully used for the treatment of acute promyelocytic leukemia (APL) in which RARα is fused to PML [12–14]. Here, PML is linked to acute promyelocytic leukemia.